Jun 10, 2025, 06:34
How Putnam’s CEO Matt Riordan Is Accelerating Cancer Therapy Adoption | ASCO 2025 Highlights
At ASCO 2025, Matt Riordan, CEO of Putnam Associates, part of Inizio Advisory, shares expert insights on the future of cancer treatment, commercialization strategy, and accelerating the adoption of next-gen therapies across clinical settings.
Highlights
- Key challenge: ensuring adoption across both academic and community oncology
- Faster clinician and patient education = faster uptake of breakthrough drugs
- Real-world strategy behind the launch of the first CAR-T therapy
- AI in oncology: overhyped or underutilized? Why human judgment still matters
- Aligning medical, commercial, and access teams around a unified strategy
- Inizio’s integrated approach: turning strategy into action across the lifecycle
- Why the real win is accelerating access for patients—without delay
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 27, 2025, 15:38
Jul 27, 2025, 15:14
Jul 27, 2025, 15:03
Jul 27, 2025, 14:26
Jul 27, 2025, 14:04
Jul 27, 2025, 13:56
Jul 27, 2025, 13:48
Jul 27, 2025, 13:42